MD, PhD @unito 🌺 Ospedale Molinette, Torino
Torino, Piemonte
Joined May 2022
- Tweets48
- Following110
- Followers97
- Likes167
Anna Amela Valsecchi retweeted
How are drug–drug interactions managed in #ProstateCancer?
Our international survey in collabs with ONCOassist reveals gaps in DDI management, highlighting the need for reliable tools & multidisciplinary collaboration.
doi.org/10.1093/oncolo/oyag3…
📣📣
Real world data about bone metastases in metastatic renal cell carcinoma (data from Meet-URO 33).
sciencedirect.com/science/ar…
Look at our last @meeturoIT review 📌
Can #biomarkers guide first-line treatment in #mRCC?
Our systematic review explores molecular & circulating biomarkers across phase III trials. Promising signals are emerging, but no validated biomarker yet guides treatment selection.
#PrecisionOncology
doi.org/10.1007/s10555-026-1…
Anna Amela Valsecchi retweeted
💥Recognising #FinantialToxicity as a prognostic factor and integrating targeted support services, educational strategies and systemic reforms could substantially improve patient outcomes, #QoL, treatment adherence and equity in #CancerCare delivery.
Learn more at the link
🔓journals.sagepub.com/share/N…
@MassimoDiMaio75 @fperrone62 @AAValsecchi
👇🏻
Have a look at this publication in @TumoriJ by @AAValsecchi Pamela Festa Maria Laura Malgarini:
Patient-reported financial toxicity within Italian public healthcare system: A cross-sectional analysis in patients with cancer
journals.sagepub.com/doi/ful…
(1/5)
Anna Amela Valsecchi retweeted
Even within the same country (Italy), use of off-label cancer drugs is subject to significant inter-hospital variability.
This leads to potential disparities in patients' access to care.
Have a look at the project by @AIOMtweet, just published on @TumoriJ:
journals.sagepub.com/eprint/…
Anna Amela Valsecchi retweeted
Bone Health and Body Composition as Predictive and Prognostic Markers in Metastatic Castration-resistant Prostate Cancer: A Meet-URO Narrative Review.
Doi: doi.org/10.1016/j.clgc.2025.…
@AAValsecchi #meeturo #clinicalgenitourinarycancer
Bellissimo congresso!
Ringrazio #AIOM per l’invito a parlare di “Oncologia, Industria e #Comunicazione: quando la scienza arriva nei titoli stampa” 📌
Talking about “Managing Toxicities Associated with #Sacituzumab Govitecan in mTNBC and HR+ MBC, with a Focus on Diarrhea and Neutropenia” w/ @VuMedi 👉🏼 vumedi.com/video/managing-to…
Anna Amela Valsecchi retweeted
Standing ovation for this trial at #ASCO25 .
Practice changing.
The problem could be the adherence to physical exercise. Accrual in the trial was very slow, because many patients refused randomization to exercise, I suppose.
Education is crucial.
Presented at #ASCO25:
A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results: nej.md/4mh5RPL
@ASCO
Anna Amela Valsecchi retweeted
Check out our open access review on the association between #QoL measures and survival endpoints in #cancer clinical trials and in clinical decision making.
Kudos to @AAValsecchi
link.springer.com/article/10…
🩵
Consegnati i Meet-URO Awards 2025:
Roberto Sabatini premiato per il contributo alla ricerca nei tumori genitourinari, Maria Concetta Cursano e Anna Amela Valsecchi vincono il Meet-URO YOUNG Award per il miglior progetto 2024.
@g_procopio_
@IstTumori
@UgoDeGiorgi
@oncodaily
Delphy consensus on the management of #AEs in patients with #mTNBC treated with #sacituzumab govitecan 🎀 academic.oup.com/oncolo/arti…
Finally published our latest work: Press releases of industry-sponsored clinical trials in #oncology: Characteristics, timing and financial impact
📄 sciencedirect.com/science/ar… @MassimoDiMaio75
